No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No-Spa, is an antispasmodic (smooth muscle relaxant) presented as an injection solution for intramuscular and intravenous use. It relieves smooth‑muscle spasm associated with abdominal, biliary, renal colic, dysmenorrhea and other related conditions.

GNH USA supplies No-Spa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

No‑Spa (drotaverine) is used to manage smooth‑muscle spasm in several gastrointestinal and urological conditions.

- Abdominal and gastrointestinal colic: provides rapid relief of painful intestinal smooth‑muscle spasm. - Renal colic: eases ureteral smooth‑muscle contraction, reducing flank pain. - Biliary colic: relaxes biliary tract smooth muscle to alleviate gall‑bladder pain. - Dysmenorrhea: diminishes uterine smooth‑muscle contractions, decreasing menstrual cramps. - Smooth‑muscle spasm associated with various conditions: improves comfort in procedures or disorders where involuntary muscle contraction is problematic.

Adverse reactions may occur with any antispasmodic injection. Monitoring for side effects is recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness after administration. - Headache: occasional throbbing pain. - Injection site pain: local discomfort at the puncture site. - Flushing: temporary reddening of skin. - Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate medical attention. - Severe hypotension: marked blood‑pressure fall leading to syncope. - Cardiac arrhythmia: irregular heart rhythm, especially in susceptible patients. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Hematologic abnormalities: rare blood‑cell count changes. - Stevens‑Johnson syndrome: severe skin reaction requiring urgent care.

Before using No‑Spa, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate blood pressure and heart status due to possible hypotensive effects. - Hepatic function: use with caution in patients with liver impairment. - Renal function: adjust or monitor in severe renal insufficiency. - Hypersensitivity: avoid in individuals with known allergy to drotaverine or formulation components. - Concomitant vasodilators: monitor for additive blood‑pressure lowering. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drotaverine may interact with other medicines that affect blood pressure or metabolism.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Other antispasmodics (e.g., papaverine): additive smooth‑muscle relaxation may cause excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., erythromycin, cimetidine): may increase drotaverine plasma levels. - Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers): monitor blood pressure for additive effects. - Diuretics: watch for electrolyte shifts that could potentiate hypotension.